Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6VA | ISIN: FR0004065605 | Ticker-Symbol: MEB
Tradegate
28.03.25
15:55 Uhr
14,920 Euro
-0,060
-0,40 %
Branche
Biotechnologie
Aktienmarkt
CAC Mid 60
1-Jahres-Chart
MEDINCELL SA Chart 1 Jahr
5-Tage-Chart
MEDINCELL SA 5-Tage-Chart
RealtimeGeldBriefZeit
14,90015,10012:13
14,90015,04028.03.

Aktuelle News zur MEDINCELL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.03.Medincell verstärkt Vorstand mit Biopharma-Experte Pascal Touchon1
06.03.Medincell strengthens board with biopharma veteran Pascal Touchon1
MEDINCELL Aktie jetzt für 0€ handeln
06.03.Medincell Strengthens its Board of Directors to Support its Growth236Regulatory News: Medincell (Paris:MEDCL): Pascal Touchon joins the Board of Directors 40 years of international experience in the biopharmaceutical industry, holding operational and strategic...
► Artikel lesen
26.02.Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA246Regulatory News: Medincell (Paris:MEDCL): Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell's corporate overview at the TD Cowen 45th Annual Healthcare Conference on Monday...
► Artikel lesen
25.02.Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder460UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults1 LAI treatment options...
► Artikel lesen
25.02.FDA accepts Teva, Medincell's supplemental application for UZEDY as bipolar I disorder treatment2
19.02.Medincell Announces Successful c.€43 Million Global Offering313Success of the operation with €42.9 million raised. Participation of US and European Healthcare specialist investors, as well as historical shareholders, in the transaction. Funds raised will...
► Artikel lesen
18.02.Medincell Launches a Global Offering for Approximately 10% of Its Share Capital357The Global Offering, for approximately 10% of the Company's share capital, is aimed at international institutional investors, via a Private Placement through an accelerated book-building process....
► Artikel lesen
10.02.Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals357Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit) Richard Malamut, Chief Medical Officer at Medincell comments:...
► Artikel lesen
06.02.The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement351The European Investment Bank (EIB) granted Medincell a €40 million credit facility in November 2022, fully drawn since July 2023 The EIB has decided to remove two financial covenants(1)...
► Artikel lesen
29.01.Medincell: UZEDY Surges to $117M in Sales in 2024, First Full Year of Commercialization302Regulatory News: Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information: About UZEDY 2024 sales: $117 million with $43 million in Q4 17%...
► Artikel lesen
15.01.Medincell: Publication of the 2025 Financial Calendar363Regulatory News: Medincell (Paris:MEDCL): Event Date Annual results 2024-2025 (April 2024-March 2025) Tuesday, June 17, 2025 General Meeting Thursday...
► Artikel lesen
12.12.24Medincell to Join the Euronext SBF 120 Index521Medincell (Paris:MEDCL) joins the Euronext SBF 120 index, which includes the 120 largest companies listed on Euronext Paris, including the CAC 40 and most of the key players in the French economy....
► Artikel lesen
10.12.24Medincell Publishes Its Consolidated Half-year Financial Results441(April 1st, 2024 September 30, 2024) Regulatory News: Medincell (Paris:MEDCL): Key highlights Sales growth of UZEDY in the United States €2.8 million in royalties invoiced by Medincell...
► Artikel lesen
09.12.24Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement409Regulatory News: Medincell (Paris:MEDCL): Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of...
► Artikel lesen
28.11.24Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024173Regulatory News: Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 10th, 2024 to present the half-year financial results (April 2024-September 2024) > Meeting in French...
► Artikel lesen
06.11.24Medincell: 25% Raise in 2024 UZEDY Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3287Regulatory News: Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today as part of its Q3 2024 results, the following information: About UZEDY Updated 2024 Revenue Outlook:...
► Artikel lesen
04.11.24Medincell's Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY at Psych Congress 20241420Medincell (Paris:MEDCL): ACCESS HERE THE COMPLETE PRESS RELEASE TEV-'749 mdc-TJK Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial period...
► Artikel lesen
04.11.24Medincell's partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY at Psych Congress 20241492Regulatory News: Medincell (Paris:MEDCL): TEV-'749 mdc-TJK Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial period of the Phase 3 SOLARIS...
► Artikel lesen
28.10.24Medincell Announces Participation in Leading Investor Conferences635Regulatory News: Members of Medincell's (Paris:MEDCL) management team will participate in the following investor conferences in November and December 2024. Truist Securities BioPharma Symposium...
► Artikel lesen
Seite:  Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1